Table 5.

The mean changes in postvoid residual urine volume from baseline to end-point

	Solifenacin succinate
	5 mg qd (N = 118)		10 mg qd (N = 118)		Tolterodine 2 mg bid (N = 118)
Postvoid residual volume (ml)		Male	Female	Male	Female	Male	Female
Baseline	N	22	96	30	87	23	95
	Mean (SD)	25.32 (31.18)	22.77 (33.45)	30.97 (28.90)	30.17 (37.89)	27.09 (28.30)	21.99 (36.50)
	Range	0.00–99.00	0.00–195.00	0.00–97.00	0.00–173.00	0.00–90.00	0.00–247.00
End of study	N	19	91	29	83	22	86
	Mean (SD)	37.68 56.39)	29.93 (39.76)	41.97 (61.68)	35.14 (60.25)	34.04 (45.10)	26.78 (35.80)
	Range	0.00–241.00	0.00–197.00	0.00–287.00	0.00–399.00	0.00–175.00	0.00–184.00
Change	N	19	91	29	82	22	86
	Mean (SD)	10.26 (48.59)	7.95 (39.26)	9.93 (54.32)	2.76 (49.31)	6.31 (39.55)	4.37 (29.42)

ANCOVA, treatment drug (p = 0.8257), gender (p = 0.2266).